All-trans retinoic acid (ATRA) in non-promyelocytic acute myeloid leukemia (AML): results of combination of ATRA with low-dose Ara-C in three elderly patients with NPM1-mutated AML unfit for intensive chemotherapy and review of the literature

Clin Case Rep. 2016 Oct 24;4(12):1138-1146. doi: 10.1002/ccr3.723. eCollection 2016 Dec.

Abstract

Based upon the clinical behavior of three patients, we suggest that the combination of low-dose Ara-C and all-trans retinoic acid may potentially be effective in some elderly patients, unfit for intensive chemotherapy, affected with NPM1-mutated acute myeloid leukemia without FLT3 mutations, warranting perspective clinical studies in these selected patients.

Keywords: All‐trans retinoic acid; NPM1‐mutated acute myeloid leukemia; elderly patients; low‐dose Ara‐C; unfitness for intensive chemotherapy.

Publication types

  • Case Reports